SOPHIA GENETICS SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.03 USD | +1.62% |
|
+1.41% | +6.79% |
| Apr. 23 | Sophia Genetics Says Nigeria's Syndicate Bio Signs on to Implement Liquid Biopsy Offering | MT |
| Apr. 23 | SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 900.4 | 132.3 | 306.8 | 328.5 | - | - |
| Enterprise Value (EV) 1 | 635.1 | -29.03 | 183.5 | 273.2 | 313.3 | 324.6 |
| P/E ratio | -10.6 x | -1.51 x | -3.86 x | -4.98 x | -6.34 x | -7.62 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 22.3 x | 2.78 x | 4.92 x | 4.14 x | 3.26 x | 2.56 x |
| EV / Revenue | 15.7 x | -0.61 x | 2.94 x | 3.44 x | 3.11 x | 2.53 x |
| EV / EBITDA | -9.36 x | 0.35 x | -2.76 x | -4.76 x | -7.09 x | -9.76 x |
| EV / FCF | -10,475,951 x | 391,300 x | - | - | - | - |
| FCF Yield | -0% | 0% | - | - | - | - |
| Price to Book | 3.27 x | 0.66 x | - | 3.62 x | 5.72 x | 6.71 x |
| Nbr of stocks (in thousands) | 63,858 | 64,211 | 65,132 | 65,301 | - | - |
| Reference price 2 | 14.10 | 2.060 | 4.710 | 5.030 | 5.030 | 5.030 |
| Announcement Date | 3/15/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 40.45 | 47.56 | 62.37 | 79.36 | 100.7 | 128.5 |
| EBITDA 1 | - | -67.88 | -82.25 | -66.49 | -57.36 | -44.2 | -33.25 |
| EBIT 1 | - | -71.49 | -87.82 | -74.83 | -60.8 | -48.65 | -38.48 |
| Operating Margin | - | -176.73% | -184.66% | -119.97% | -76.61% | -48.32% | -29.95% |
| Earnings before Tax (EBT) 1 | - | -73.51 | -87.58 | -78.5 | -63.79 | -49.64 | -48.7 |
| Net income 1 | -39.34 | -73.68 | -87.45 | -78.98 | -66.1 | -53.01 | -44.97 |
| Net margin | - | -182.14% | -183.87% | -126.63% | -83.29% | -52.65% | -34.99% |
| EPS 2 | -0.9300 | -1.330 | -1.360 | -1.220 | -1.010 | -0.7933 | -0.6600 |
| Free Cash Flow | - | -60.62 | -74.19 | - | - | - | - |
| FCF margin | - | -149.87% | -155.99% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/24/21 | 3/15/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10.36 | 10.94 | 10.86 | 11.67 | 11.65 | 13.38 | 13.97 | 15.05 | 16.3 | 17.05 | 15.59 | 17.42 | 21.6 | 24 | 20.89 |
| EBITDA | -19.5 | -19.78 | -23.83 | -22.69 | -22.19 | -13.53 | -17.4 | -17.78 | -14.34 | -16.96 | - | - | -15.2 | -15.4 | -13.3 |
| EBIT 1 | -20.5 | -21.01 | -25.02 | -24.08 | -23.64 | -15.08 | -19.29 | -20.05 | -16.54 | -18.95 | -16.25 | -14.25 | -13.53 | -12.59 | -16.59 |
| Operating Margin | -197.91% | -192.09% | -230.37% | -206.39% | -202.94% | -112.69% | -138.1% | -133.17% | -101.48% | -111.13% | -104.29% | -81.81% | -62.63% | -52.46% | -79.4% |
| Earnings before Tax (EBT) 1 | -20.76 | -21.9 | -25.25 | - | -23.42 | -14.23 | -19.59 | -21.32 | -13.52 | -24.05 | -17.49 | -14.58 | -14.93 | -14.37 | -16.53 |
| Net income 1 | -21.24 | -21.37 | -25.49 | - | -23.31 | -13.97 | -19.7 | -21.4 | -13.82 | -24.06 | -17.49 | -14.58 | -15.08 | -14.52 | -16.53 |
| Net margin | -205.07% | -195.43% | -234.67% | - | -200.12% | -104.39% | -141.06% | -142.13% | -84.79% | -141.13% | -112.21% | -83.7% | -69.82% | -60.51% | -79.12% |
| EPS 2 | -0.3500 | -0.3300 | -0.4000 | -0.3900 | -0.3600 | -0.2200 | -0.3100 | -0.3300 | -0.2100 | -0.3700 | -0.2833 | -0.2567 | -0.2400 | -0.2333 | -0.2467 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/15/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/7/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 265 | 161 | 123 | 55.3 | 15.1 | 3.88 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -60.6 | -74.2 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -39.2% | -36.8% | -44.9% | -60.4% | -80.1% | -76.4% |
| ROA (Net income/ Total Assets) | - | -32.6% | -31% | - | - | - | - |
| Assets 1 | - | 226.1 | 282 | - | - | - | - |
| Book Value Per Share 2 | - | 4.310 | 3.120 | - | 1.390 | 0.8800 | 0.7500 |
| Cash Flow per Share | - | - | -1.090 | - | - | - | - |
| Capex 1 | - | 2.68 | 4.1 | 1.49 | 2 | 2.2 | 2.8 |
| Capex / Sales | - | 6.63% | 8.61% | 2.4% | 2.52% | 2.19% | 2.18% |
| Announcement Date | 5/24/21 | 3/15/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.03
USD
Average target price
8.667
USD
Spread / Average Target
+72.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.79% | 328M | |
| +8.05% | 3,020B | |
| +5.58% | 82.93B | |
| +3.69% | 76.85B | |
| -14.62% | 53.04B | |
| +31.16% | 50.15B | |
| -24.56% | 46.55B | |
| +17.75% | 41.41B | |
| +55.21% | 35.63B | |
| -10.24% | 24.64B |
- Stock Market
- Equities
- SOPH Stock
- Financials SOPHiA GENETICS SA
